Clinic of Dermatology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 60126 Ancona, Italy.
Int J Mol Sci. 2023 Aug 3;24(15):12383. doi: 10.3390/ijms241512383.
Pembrolizumab has been shown to increase survival in patients with metastatic melanoma. Considering the numerous oncoming studies, we decided to conduct a narrative review of the latest efficacy evidence regarding the use of pembrolizumab, alone or in combination, in patients with metastatic melanoma. A search was conducted in PubMed using "pembrolizumab," and "metastatic melanoma" as keywords, considering studies from 2022 onward. We reviewed pembrolizumab and associations, cost-effectiveness, virus, advanced acral melanoma, long-term outcomes, real-life data, biomarkers, obesity, and vaccines. In conclusion, pembrolizumab is a fundamental option in the therapy of metastatic melanoma. However, a certain group of patients do not respond and, therefore, new combination options need to be evaluated. In particular, the use of vaccines tailored to tumor epitopes could represent a breakthrough in the treatment of resistant forms. Further studies with larger sample numbers are needed to confirm the preliminary results.
帕博利珠单抗已被证明可提高转移性黑色素瘤患者的生存率。考虑到即将开展的众多研究，我们决定对帕博利珠单抗单独或联合用于转移性黑色素瘤患者的最新疗效证据进行叙述性综述。在 PubMed 中使用“pembrolizumab”和“metastatic melanoma”作为关键字进行检索，考虑了 2022 年以后的研究。我们回顾了帕博利珠单抗及其联合用药、成本效益、病毒、晚期肢端黑色素瘤、长期结局、真实世界数据、生物标志物、肥胖和疫苗。总之，帕博利珠单抗是转移性黑色素瘤治疗的基本选择。然而，有一定比例的患者对此没有反应，因此需要评估新的联合用药选择。特别是，使用针对肿瘤表位的疫苗可能是治疗耐药形式的突破。需要进一步进行样本数量更大的研究来证实初步结果。
